Screener
Quest Diagnostics DGX Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Quest Diagnostics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The source filing: Quest Diagnostics’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001022079-26-000070
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from borrowings | 494 | 400 |
| Repayments of debt | (501) | (1,001) |
| Purchases of treasury stock | (102) | — |
| Exercise of stock options | 81 | 42 |
| Employee payroll tax withholdings on stock issued under stock-based compensation plans | (38) | (42) |
| Dividends paid | (184) | (174) |
| Distributions to noncontrolling interest partners | (22) | (29) |
| Other financing activities, net | (109) | (50) |
Cover / Front Matter
FAQ
- What is Quest Diagnostics's stock issuance proceeds?
- Quest Diagnostics (DGX) reported stock issuance proceeds of $16M in Q2 2026.
- How has Quest Diagnostics's stock issuance proceeds changed year-over-year?
- Quest Diagnostics's stock issuance proceeds increased by 23.1% year-over-year, from $13M to $16M.
- What is the long-term trend for Quest Diagnostics's stock issuance proceeds?
- Over 4 years (2021 to 2025), Quest Diagnostics's stock issuance proceeds has grown at a -11.5% compound annual growth rate (CAGR), from $129M to $79M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about Quest Diagnostics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude